PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för danusertib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

35 hits

Bibliografisk träff 2024-06-10

Understanding the Differences of Danusertib's Residence Time in Aurora Kinases A/B: Dissociation Paths and Key Residues Identified using Conventional and Enhanced Molecular Dynamics Simulations.

Bravo-Moraga F, Bedoya M, Vergara-Jaque A, Alzate-Morales J.

J Chem Inf Model · journal article · DOI 10.1021/acs.jcim.4c00387

Bibliografisk träff 2024-03-21

Suppression of NSCLC progression via the co-administration of Danusertib, an AURK inhibitor, and KRIBB11, an HSF1 inhibitor.

Zhang X, Lei Y, Chen X, He J, Liu Z, Zhu W, Xu Y, Jin X.

Biochem Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bcp.2024.116155

Bibliografisk träff 2024-02-01

The Supression of Migration and Metastasis via Inhibition of Vascular Endothelial Growth Factor in Pancreatic Adenocarcinoma Cells Applied Danusertib.

Alabaş E, Ata Özçimen A.

Turk J Gastroenterol · research-article; journal article · DOI 10.5152/tjg.2024.22319

Bibliografisk träff 2023-12-20

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.

Takarada JE, Cunha MR, Almeida VM, Vasconcelos SNS, Santiago AS, Godoi PH, Salmazo A, Ramos PZ, Fala AM, de Souza LR, Da Silva IEP, Bengtson MH, Massirer KB, Couñago RM.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117561

Bibliografisk träff 2022-11-01

Pan-Aurora Kinase Inhibitor Danusertib Induces Apoptosis of Epstein-Barr Virus-transformed B-Cells Through Caspase and Endoplasmic Reticulum Stress Signaling.

Kim JS, Hur DY.

Anticancer Res · journal article · DOI 10.21873/anticanres.16033

Bibliografisk träff 2022-09-07

A close look into the biological and synthetic aspects of fused pyrazole derivatives.

Li MM, Huang H, Pu Y, Tian W, Deng Y, Lu J.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114739

Bibliografisk träff 2022-02-15

Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity.

Bijian K, Wernic D, Nivedha AK, Su J, Lim FPL, Miron CE, Amzil H, Moitessier N, Alaoui-Jamali MA.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.1c01031

Bibliografisk träff 2021-10-01

The effect of danusertib, an Aurora kinase inhibitor, onto the cytotoxicity, cell cycle and apoptosis in pancreatic ductal adenocarcinoma cells.

Kirbiyik IA, Ozcimen AA.

J Cancer Res Ther · journal article · DOI 10.4103/jcrt.jcrt_827_19

Bibliografisk träff 2021-03-10

Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.

Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson JY, Richard S, Raynal NJ.

Clin Epigenetics · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13148-021-01037-1

Bibliografisk träff 2020-02-01

Augmentation of danusertib's anticancer activity against melanoma by blockage of autophagy.

Shang YY, Yu N, Xia L, Yu YY, Ma CM, Jiao YN, Li YF, Wang Y, Dang J, Li W.

Drug Deliv Transl Res · research support, non-u.s. gov't; journal article · DOI 10.1007/s13346-019-00668-5

Bibliografisk träff 2020-01-31

Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.

Bo YX, Xiang R, Xu Y, Hao SY, Wang XR, Chen SW.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2020.115351

Bibliografisk träff 2020-01-31

Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.

Fan C, Zhong T, Yang H, Yang Y, Wang D, Yang X, Xu Y, Fan Y.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2020.112108

Bibliografisk träff 2018-10-26

Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.

Veale CGL, Hoppe HC.

Medchemcomm · research-article; journal article · DOI 10.1039/c8md00319j

Bibliografisk träff 2018-02-27

Targeting hepatocarcinogenesis model in C56BL6 mice with pan-aurora kinase inhibitor Danusertib.

Gavriilidis P, Poutahidis T, Giakoustidis A, Makedou K, Angelopoulou K, Hardas A, Andreani P, Zacharioudaki A, Saridis G, Gargavanis A, Louri E, Antoniadis N, Karampela E, Psychalakis N, Michalopoulos A, Papalois A, Iliadis S, Mudan S, Azoulay D, Giakoustidis D.

J Cancer · research-article; journal article · DOI 10.7150/jca.22329

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Bibliografisk träff 2017-08-24

A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.

Borisa AC, Bhatt HG.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2017.08.045

Bibliografisk träff 2015-11-13

Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.

Zi D, Zhou ZW, Yang YJ, Huang L, Zhou ZL, He SM, He ZX, Zhou SF.

Int J Mol Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/ijms161126018

Bibliografisk träff 2015-10-24

In situ electrochemical evaluation of dsDNA interaction with the anticancer drug danusertib nitrenium radical product using the DNA-electrochemical biosensor.

Diculescu VC, Oliveira-Brett AM.

Bioelectrochemistry · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bioelechem.2015.10.004

Bibliografisk träff 2015-04-17

A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.

Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, Mariani M, Capolongo L, Carpinelli P, Davite C, Kantarjian H, Cortes JE.

Haematologica · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.3324/haematol.2014.115279

Retracted publication 2015-03-02

Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.

Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Pan SY, Chen XW, Zhou SF.

Drug Des Devel Ther · retracted publication; research support, non-u.s. gov't; research-article; journal article · DOI 10.2147/dddt.s74964

Bibliografisk träff 2014-11-24

SAR156497, an exquisitely selective inhibitor of aurora kinases.

Carry JC, Clerc F, Minoux H, Schio L, Mauger J, Nair A, Parmantier E, Le Moigne R, Delorme C, Nicolas JP, Krick A, Abécassis PY, Crocq-Stuerga V, Pouzieux S, Delarbre L, Maignan S, Bertrand T, Bjergarde K, Ma N, Lachaud S, Guizani H, Lebel R, Doerflinger G, Monget S, Perron S, Gasse F, Angouillant-Boniface O, Filoche-Rommé B, Murer M, Gontier S, Prévost C, Monteiro ML, Combeau C.

J Med Chem · journal article · DOI 10.1021/jm501326k

Bibliografisk träff 2014-05-01

Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.

Patel G, Roncal NE, Lee PJ, Leed SE, Erath J, Rodriguez A, Sciotti RJ, Pollastri MP.

Medchemcomm · research-article; journal article · DOI 10.1039/c4md00045e

Bibliografisk träff 2013-08-30

Selectivity data: assessment, predictions, concordance, and implications.

Gao C, Cahya S, Nicolaou CA, Wang J, Watson IA, Cummins DJ, Iversen PW, Vieth M.

J Med Chem · journal article · DOI 10.1021/jm400798j

Bibliografisk träff 2012-07-31

The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.

Ochiana SO, Pandarinath V, Wang Z, Kapoor R, Ondrechen MJ, Ruben L, Pollastri MP.

Eur J Med Chem · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ejmech.2012.07.038

Bibliografisk träff 2012-07-02

Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.

Fraedrich K, Schrader J, Ittrich H, Keller G, Gontarewicz A, Matzat V, Kromminga A, Pace A, Moll J, Bläker M, Lohse AW, Hörsch D, Brümmendorf TH, Benten D.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-11-2968

Bibliografisk träff 2012-01-13

Danusertib, an aurora kinase inhibitor.

Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2012.652303

Bibliografisk träff 2010-12-01

Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.

Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll J.

Cancer Res · journal article · DOI 10.1158/0008-5472.can-10-2101

Bibliografisk träff 2010-08-01

A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.

Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T.

J Med Chem · research-article; journal article · DOI 10.1021/jm901808w

Bibliografisk träff 2010-02-25

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.

Steeghs N, Mathijssen RH, Wessels JA, de Graan AJ, van der Straaten T, Mariani M, Laffranchi B, Comis S, de Jonge MJ, Gelderblom H, Guchelaar HJ.

Invest New Drugs · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-010-9405-7

Bibliografisk träff 2010-01-01

Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.

Gontarewicz A, Brümmendorf TH.

Recent Results Cancer Res · review; journal article · DOI 10.1007/978-3-642-01222-8_14